March 17, 2025  Home  |  About Us  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages  |  Contact Us  |  中文
HeBei Med  2018, Vol. 24 Issue (10): 1727-1730    DOI: 10.3969/j.issn.1006-6233.2018.10.035
Current Issue | Archive | Adv Search |
Clinical Efficacy and Safety Analysis of Loratadine and Azelastine Nasal Spray in the treatment of Allergic Rhinitis
ZHU Dan
Fuxin Center Hospital, Liaoning Fuxing 123000, China
Download: PDF (1269 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  Objective: To study the clinical efficacy of loratadine combined with azelastine nasal spray in the treatment of allergic rhinitis. Methods: 243 patients with allergic rhinitis were enrolled in our hospital from February 2015 to January 2017. All patients were divided into control group (n=119) and study group (n=124) according to the random number table method. The patients in the control group were treated with azelastine nasal spray. The patients in the study group were treated with desloratadine and azelastine nasal spray, and the IL-4, IL-6, IL-10 and other inflammations were compared between the two groups before and after treatment. Factor levels, VCAM-1, IgE levels before and after treatment, symptom scores before and after treatment, and clinical efficacy after treatment. Results: There was no significant difference in the levels of IL-4, IL-6 and IL-10 before treatment between the two groups (P>0.05). The levels of IL-4, IL-6 and IL-10 were significantly lower in the study group than in the control group after treatment. Group, and two groups of patients after treatment significantly lower than their respective treatment, and were statistically significant (P<0.05). There was no significant difference in the levels of VCAM-1 and IgE between the two groups before treatment (P>0.05). The levels of VCAM-1 and IgE in the study group were significantly lower than those in the control group after treatment, and the two groups were significantly lower than the respective treatment after treatment. Before and with statistical differences (P<0.05). There was no significant difference in symptom scores before treatment between the two groups in terms of nasal itching, nasal congestion, runny nose, and sneezing (P>0.05). Symptom scores after treatment in the study group were significantly lower than those in the control group, and both groups were significantly lower after treatment. Before each treatment, there was a statistical difference (P<0.05). The total effective rate of the control group was 79.83%; the total effective rate of the study group was 96.77%. There was a statistically significant difference in the total effective rate between the two groups (P<0.05). The incidence of adverse reactions in the control group was 3.36%; the incidence of adverse reactions in the study group was 4.03%. Adverse reactions resolved spontaneously after the end of treatment, and no abnormalities of kidney, liver and heart function were seen. Conclusion: Desloratadine combined with azelastine nasal spray can reduce inflammatory reactions, reduce serum inflammatory factors, VCAM-1 and IgE levels, significantly improve clinical symptoms, improve treatment efficiency, and have good therapeutic effect.
Key wordsAllergic rhinitis      Desloratadine      Azelastine nasal spray     
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
ZHU Dan
Cite this article:   
ZHU Dan. Clinical Efficacy and Safety Analysis of Loratadine and Azelastine Nasal Spray in the treatment of Allergic Rhinitis[J]. HeBei Med, 2018, 24(10): 1727-1730.
URL:  
http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.10.035     OR     http://www.hbyxzzs.cn/EN/Y2018/V24/I10/1727
Copyright © Editorial Board of HeBei Med
Supported by:Beijing Magtech